Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sino Biopharm is one of the largest pharmaceutical companies in China, focused on oncology, hepatology, and respiratory diseases, with multiple products approved and marketed. Anlotinib (targeting VEGFR, PDGFR, FGFR) is a well-known commercialized small molecule for cancer; Penpulimab is a commercialized monoclonal antibody for immuno-oncology. The company is also active in biosimilars, generic drugs, and modernized Chinese medicine, with recent expansion into biopharma platforms such as bispecific antibodies and mRNA delivery, especially through its subsidiary invoX[1][2][3][4][5].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Sino Biopharm.